RSV drug, Beyfortus, gets FDA nod for protecting newborns and infants

NewsDesk@bactiman63 The U.S. Food and Drug Administration (FDA) has approved Sanofi and AstraZeneca'sBeyfortusTM (nirsevimab-alip) for the prevention of respiratory syncytial virus (RSV) lower respiratory tract disease (LRTD) in newborns and infants born during or entering their first RSV season, and for children up to 24 months of age who remain vulnerable to severe RSV disease [...]

The post RSV drug, Beyfortus, gets FDA nod for protecting newborns and infants appeared first on Outbreak News Today.